Hyperhomocysteinemia, Hypertension
Conditions
Keywords
Folic acid, Renal function decline, Hypertension, Hyperhomocysteinemia, Chronic kidney disease, MTHFR C677T genotype, Randomized controlled trial
Brief summary
The purpose of this trial is to confirm that enalapril maleate and folic acid tablets is more effective in preventing renal function decline among the patients with primary hypertension when compared to enalapril maleate.
Detailed description
Elevated blood concentration of homocysteine (Hcy) has been suggested as a modifiable, independent risk factor for coronary artery disease, stroke, and deep vein thrombosis. Prevalence of hyperhomocysteinemia and folic acid deficiency in China are significantly higher than those in Europe and USA. The investigators' preliminary research demonstrated that blood concentration of Hcy was negatively correlated to estimated glomerular filtration rate (eGFR), a key index of kidney function. However, the question as to whether Hcy-lowering therapy with folic acid can reduce the risk of chronic kidney disease(CKD) remains to be answered. This study, exploiting the hypertensive population of CSPPT trial (ClinicalTrials.gov register number: NCT00794885), is intended to compare the effects of enalapril maleate and folic acid tablets versus enalapril maleate in preventing renal function decline among the patients with primary hypertension. The results from this trial may have the potential to transform current clinical and public health findings into practice in the prevention of chronic kidney disease(CKD) in China.
Interventions
DRUGEnalapril maleate and folic acid tablets
Enalapril maleate and folic acid tablets, (10mg/0.8mg)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
Sponsors
Nanfang Hospital, Southern Medical University
Shenzhen Ausa Pharmed Co.,Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
45 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* BP≥140/90 mmHg in both of the two screening visits or currently under anti-hypertension treatment; * 45-75 years old; * Successful determination of methylenetetrahydrofolate reductase (MTHFR) C677T genotype; * For pre-menopausal women, agreed to use contraceptives during the trial; * Signed the written informed consent.
Exclusion criteria
* Having a history of stroke; * Having a history of myocardial infarction; * Having a history of physician diagnosed heart failure; * Post- coronary revascularization; * Severe somatic disease such as cancer; * Secondary hypertension; * Congenital or acquired organic heart diseases; * Contraindicated to angiotensin-converting enzyme inhibitor (ACEI); * Having a history of ACEI adverse effects; * Currently long-term use of folic acid or vitamin B12 or vitamin B6; * Pregnant or child breastfeeding women; * Severe mental disorders; * Lab tests indicating abnormal liver or kidney function; * Unwilling to participate the trial; * Unwilling to change the current antihypertensive treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Renal function decline | Serum creatinine was examined at baseline and at the final visit (5 years) of the trial. | Renal function decline was defined based on one of more of the following : (1) A certain drop in eGFR, was defined as a drop in GFR category (≥90\[G1\], 60-89\[G2\], 45-59\[G3a\], 30-44\[G3b\], 15-29\[G4\], \<15\[G5\] ml/min/1.73m2) accompanied by a 25% or greater drop in eGFR from baseline; (2) Rapid progression, was defined as a sustained decline in eGFR of more than 5 ml/min/1.73m2/yr. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Average decline rate in eGFR (ml/min/1.73m2/yr). | Serum creatinine was examined at baseline and at the final visit (5 years) of the trial. | — |
| New-onset chronic kidney disease based on eGFR（eGFR<60 ml/min/1.73 m2） | Serum creatinine was examined at baseline and at the final visit (5 years) of the trial. | — |
| New-onset albuminuria | Albuminuria was examined at baseline and at the final visit (5 years) of the trial. | — |
| A composite of renal events. | Every 3 months during the trial, up to 5 years | The composite endpoint is consisted of: 1)End stage renal disease (ESRD);2)Doubling of serum creatinine; and 3)Renal disease-induced death. |
Countries
China
Outcome results
None listed